MUM1L1 Inhibitors
MUM1L1 Inhibitors target essential regulatory pathways, therefore modulating the functional activity of MUM1L1 within the cell. For instance, kinase inhibitors that prevent phosphorylation events critical for MUM1L1's activity serve as indirect inhibitors by obstructing the post-translational modifications necessary for MUM1L1 to exert its cellular functions. Moreover, certain inhibitors disrupt the PI3K/AKT/mTOR and MAPK/ERK signaling cascades, which are fundamental for cell survival, proliferation, and differentiation, where MUM1L1 is likely a contributing factor. Specifically, these inhibitors act by either stabilizing regulatory proteins that naturally constrain MUM1L1's role or by attenuating the activation of the kinases that facilitate the signaling pathways in which MUM1L1 is involved. As a result, the inhibition of these kinases translates to a diminished influence of MUM1L1 in cell cycle progression and other dependent processes.
Additionally, inhibitors that target components of the cell cycle machinery or DNA repair processes can indirectly diminish MUM1L1 activity by altering the cellular environment in which it operates. For instance, inhibitors that interfere with mitotic spindle assembly or those that antagonize key regulators of the cell cycle, such as MDM2, can lead to a state where MUM1L1's involvement in cell division or its response to DNA damage is hindered. By inducing an accumulation of DNA damage or promoting cell cycle arrest and apoptosis through the stabilization of tumor suppressors, these compounds effectively limit the functional scope of MUM1L1. Proteasome inhibitors further contribute to the inhibition by disrupting proteostasis, potentially leading to an environment that is less conducive for MUM1L1 activity due to an overload of regulatory proteins.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that targets a wide range of kinases involved in cell signaling. Inhibition of these kinases can lead to a downstream reduction in MUM1L1 activity by preventing phosphorylation events that MUM1L1 may be involved in. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A phosphoinositide 3-kinase (PI3K) inhibitor that disrupts PI3K/Akt signaling. As this pathway is crucial for cell survival and growth, its inhibition can indirectly decrease MUM1L1 function due to reduced cellular proliferation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that impairs the mTOR signaling pathway, which is implicated in cell growth and survival. By inhibiting this pathway, the activity of downstream proteins such as MUM1L1 can be indirectly reduced. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A selective inhibitor of MEK1/2, which are upstream of the ERK pathway. Inhibition of this pathway can lead to a decrease in MUM1L1 activity due to reduced transcriptional activity linked to cell cycle progression and differentiation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that can interrupt the p38 signaling pathway, potentially decreasing MUM1L1 activity by affecting stress response and inflammation-related signaling where MUM1L1 might play a role. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that can lead to an accumulation of proteins destined for degradation. This may indirectly affect MUM1L1 activity by disrupting protein turnover and signaling pathways that MUM1L1 is part of. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
A histone deacetylase inhibitor that alters chromatin structure and gene expression. By changing the transcriptional landscape, it can indirectly reduce MUM1L1 activity by affecting genes that regulate MUM1L1’s function or expression. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
A Hedgehog signaling pathway inhibitor that can lead to a reduction in MUM1L1 activity by affecting developmental and growth-related processes where MUM1L1 may be involved. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
An inhibitor of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pumps, leading to disruption of calcium homeostasis. This can indirectly decrease MUM1L1 activity by affecting calcium-dependent signaling pathways involving MUM1L1. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
A glycolysis inhibitor that mimics glucose, leading to disruption of ATP production. This can indirectly affect MUM1L1 activity by hindering cellular energy metabolism, which is essential for the function of many signaling proteins. | ||||||